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 Amyotrophic Lateral Sclerosis (ALS) is a debilitating neurodegenerative disease 
with no known cause or cure. Through a combination of an open market-space, scientific 
curiosity, and the humanitarian motivation to advance medicine, every treatment option 
imaginable has been attempted for this condition in the hopes of finding a cure. This 
analysis incorporates 5026 paired treatment-to-control data points of the G93A SOD1 
mouse model, the most commonly tested ALS model, in an effort to organize the vast 
amount of published data in the field and evaluate which approaches are most promising 
for further experimentation. An ANOVA analysis was completed comparing nine different 
pathophysiological treatment approaches to ALS as a function of seven stages of disease 
progression throughout the entire lifespan of the mice. Treatment efficacy was evaluated 
based on how well the treatment improved three disease metrics compared to their own 
experimental control. Patterns emerged for overall disease benefit, as well as for the three 
modality assessments including onset delay, survival prolongment, and general health 
scores. Combination treatments that fit into more than one category also performed better 
than individual therapies later in life. Interestingly, most treatments were administered 
before disease onset, yet benefit was almost solely found post-onset. These results suggest 
that patients may benefit from a targeted pro-active combinatorial treatment approach to 
combat the multiple failed regulations and general homeostatic instability characteristic of 
ALS. Such a conclusion correlates with the trend towards complex personal medicine 
treatment plans in other multifactorial diseases.
 1 
INTRODUCTION 
Amyotrophic Lateral Sclerosis was unfamiliar to the general public until the ALS 
Association’s Ice Bucket Challenge in 2014 brought attention to this debilitating and 
invariably fatal disease. While the social media phenomenon raised money and awareness, 
ALS is still as deadly and far from a cure as ever: only one FDA approved drug manages 
to extend patient survival by a matter of months, but the negative side-effects make its 
benefits controversial (1). The problem lies in the inherent pathophysiological complexity 
of this neurodegenerative condition. Familiarly occurring in only 10% of cases, no clear 
etiology has been identified, but rather a combination of proposed factors could explain 
how ALS sporadically befalls 90% of patients (2). 
While all ALS mouse models experience the same multifactorial issues, which are 
also shared across many other motor-degenerative diseases, the G93A SOD1 (G93A) 
familial model is most commonly tested. Treatments spanning everything from melatonin 
(3) to bee venom (4) have been evaluated. This vast range of approaches has previously 
been organized into 9 defined categories based on which pathophysiological function 
ontology the treatment intends to improve (5). A prior examination of these categories has 
demonstrated oscillating relationships between the processes, suggesting that the diseased 
system experiences a homeostatic instability when trying to overcome one problem, but 
overcompensating and aggravating a different one (6). Bearing this dynamic and ever-
changing condition in mind, all of these previous treatments may have failed due to only 
managing one ontological instability when multiple factors need to be addressed 
simultaneously. 
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 Despite extensive effort to find the exact cause and treatment for ALS as well as 
other complex diseases, they remain a mystery to the field. One potential explanation for 
this elusion might be that many researchers only consider one aspect of the disease, and 
therefore only attempt to treat a fraction of the problem. Our study compares the treatment 
effect of all 9 ALS ontological treatment approaches over 7 time spans throughout the 
G93A mice lifespan. By including all of the major instabilities in the entire disease 
progression with such a large dataset, this analysis has a high chance of catching any 
relations that exist. Following an all-encompassing analysis, the benefit of all 9 approaches 
will be determined specifically for their effectiveness in delaying onset, improving health 
status, and prolonging mice survival time. 
Correlating the multifactorial nature of complex diseases is a multiple treatment 
approach. The idea of targeted polytherapy is nothing new; personalized combination 
treatments have demonstrated clinical success in cancer patients (7). Recent clinical studies 
have shown the potential of adapting this approach into other diseases, including ALS (8, 
9). However, the question becomes how to find the best combinations when there is already 
a struggle to find one single beneficial treatment? 
In an effort to answer this question, evaluating and comparing the treatment 
efficacies of previous studies could narrow down the options. Our assessment of the most 
promising ALS treatments as a function of time could contribute to the creation of a more 
concrete therapeutic strategy for disease management: the most promising results can be 




Due to its inherent complexity, no cure has yet been found for amyotrophic lateral 
sclerosis (ALS). Only 5-10% of patients have an affirmative family history for ALS, thus 
the remaining 90-95% ALS patients are sporadic cases with unknown etiology (10). 
Multiple studies have proposed additional factors potentially associated with ALS besides 
genetics, including environmental factors and pre-existing disease or conditions (11). In 
recent years, more researchers have acknowledged that ALS is, in fact, a multi-factorial 
pathology, involving the interplay of several pathogenic pathways that propagate the 
spread of motoneuron death (12). The principal experimental model utilized to study 
ALS pathophysiology, the SOD1 G93A transgenic ALS mouse model, has a precisely 
known mutation and yet, the exact initiating disease mechanisms remain unclear.  
However, thousands of experiments have revealed a multitude of factors that are 
contributing to disease progression. These complex interactions in the multi-factorial 
ALS pathophysiology have been simulated in temporal, multi-scalar computational 
models, which discovered the presence of mathematically unstable dynamics, or system 
instabilities.  Despite innate compensatory regulation, the system instability and 
insufficient regulation prevents the re-establishment of homeostasis post-ALS onset, an 
observation dubbed as “homeostatic instability” (13). In short, ALS is not a one-factor 
disease but rather, a system-level instability.  Future treatment strategies must embrace a 
holistic approach that extends beyond the search for an autonomous single root cause 
responsible for all cases of ALS but instead, focuses on the re-establishment of system 
homeostasis-- irrespective of the initiating cause. 
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1.1 Modality assessment can distort apparent treatment efficacy 
Hundreds of journal articles have published results assessing potential therapeutic 
strategies in the SOD1 G93A mouse model, but unfortunately, there is no universal 
standard to assess level of benefit. The quantifiable data may evaluate anything from 
onset tremors to grip strength to survival.  Even an outcome seemingly as simple as 
“survival” may have more than 15 experimental definitions.  Some preclinical treatment 
approaches are cited to be particularly effective in delaying ALS onset, others in slightly 
prolonging survival, and still others in improving standard post-onset health status. 
Infrequently does a study examine all such outcomes, and if it does, even more rarely is 
the benefit conferred across all outcome assessment modalities.  For example, treatment 
targeting inflammation is generally cited as delaying onset, but appears to be less 
effective if treatment is initiated in later disease stages (14). Another example is 
apoptosis, where a study showed that blocking apoptosis towards end-stage conferred no 
prolonged survival benefit, but it did improve the quality of life scores of the mice (15). 
Conversely, another study showed that treatments targeting axonal transport are only 
effective in prolonging survival (16). Interestingly, axonal transport deficiency occurs 
very early in the disease progression (17), with the anterograde mitochondrial transport 
most affected by the SOD1 G93A mutation. 
Thus, it is evident that treatments may be more beneficial in improving only survival, 
only time of onset,  only quality of life scores (e.g. rotarod performance, grip strength, 
body weight, etc.), combinations thereof, or none of the above (18). Further research into 
which preclinical assessments are most reliable for ultimately predicting clinical relevant 
efficacy will lead to universal standards for experimental assessment modalities.   
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However, in the meantime, the specific outcome metric utilized as an experimental 
assessment modality must be considered when comparing treatment efficacy among 
studies. 
1.2 Combination therapy is the future of ALS treatment 
Combination therapy treatments are those categorized as targeting more than 
one pathophysiological treatment category. Within the literature, dual-treatment usage 
such as rasagiline and riluzole (19), minocycline and creatine (20), lithium and 
Neu2000 (21), and Minocycline + riluzole + nimodipine (22), have either extended 
survival, delayed onset, or accomplished both more effectively than either of the 
individual treatments dispensed alone. A polytherapy approach to such a complex 
disease could potentially help with treating the multiple factors involved in ALS 
instability; it is unlikely that one drug can tackle all necessary pathways.  
A personalized combination therapy approach was first introduced in cancer 
patients where it has repeatedly demonstrated clinical success in the oncological field. 
Randomized, placebo-controlled clinical trials for ALS patients using combination 
therapy, such as minocycline-creatine and celoxicob-creatine, have largely 
outperformed individual therapies in slowing disease progression in patients (23). The 
latter two treatment concepts were adapted from the results of a murine model 
experiment, demonstrating the potential value and applicability of preclinical models. 
While a combination treatment approach could provide more benefit to the 
patient, it will take time to determine which combinations are both safe and effective. 
The SOD1 G93A mouse model is a good preclinical starting point, as the results from 
this model are directly applicable to familial SOD1 G93A ALS cases; although ALS 
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corresponding to the SOD1 G93A mutation does not precisely align with sporadic 
ALS, they do share many of the same pathophysiological deficiencies (24). Using 
Riluzole as the first part of a combination may help expedite a successful clinical 
combination therapy, considering it already has FDA approval, owing to the fact its 
efficacy and safety profile is well established (25).  
1.3 Project Scope 
The long-term goal of the present study is to jump-start the process of 
selecting the most viable potential drug combinations by imploring a large sample 
size, determining the impact of temporal dynamics/disease stage on treatment 
efficacy, and considering the assessment modality utilized to determine efficacy.  This 
study utilizes multi-treatment meta-analysis to assess individual treatment 
effectiveness in improving disease parameters throughout the various stages of 
disease progression of SOD1 G93A transgenic mice.  A large-scale aggregated 
analysis can ameliorate discrepancies in the literature and provide justification for 
logistical planning of future studies. Finally, an assessment of the most promising 
ALS treatments as a function of time and assessment modality will provide a 
foundation for the eventual creation of concrete and personalized combination 
therapeutic strategy for disease management--one that compensates for the dominant 
instability occurring at each diseases stage and anticipates the next one as the 
dynamics of the pathophysiology evolve.
 1 
MATERIALS AND METHODS  
1.4 Study Design 
In an effort to evaluate and compare the treatment efficacies of previous studies, this 
analysis of the most promising ALS treatments as a function of time and assessment 
modality could contribute to the creation of a more concrete therapeutic strategy for disease 
management. 
1.5 Inclusion/Exclusion Criteria 
3412 publications were found from a PubMed search in July 2016 with 
“Amyotrophic Lateral Sclerosis” or “ALS” and “mouse” or “G93A” in the title or abstract 
(5, 6). These articles were downloaded using e-journal subscriptions available at the 
libraries of Georgia Institute of Technology and Emory University. Treatment information 
and results were systematically entered into a relational database using FileMaker Pro 14 
Advanced and underwent rigorous quality control procedures (7). 
 Of these downloaded articles, 1232 had recorded quantifiable measures of mouse 
health and were identified for inclusion. Of this subgroup, 324 tested SOD1 G93A ALS 
mice, and 291 of those were treated with the intention of ameliorating disease conditions. 
So that treatments from each individual paper could be compared based on performance 
relative to control, consistency between mice age and disease stages was also an inclusion 
criterion. Only articles with high copies of SOD1 G93A-B6SJL-Tg ALS mice, SOD1 
G93A-B6Cg-Tg ALS mice, mice with unstated genetic background, or B6SJL mice 
backcrossed with other genetic backgrounds with disease progression timelines consistent 
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with the high copy B6SJL mice and genotype-matched controls were included. The final 
constraint for inclusion required that articles must have data spanning at least two disease 
stages, so that the effect of treatments over the duration of disease remained the focus 
instead of the effectiveness at alleviating symptoms at a certain point. 199 published 
articles met all criteria and were included in the analysis. 
1.6 Treatment Category Definitions 
All treatments were organized into one of the nine pathophysiological categories 
based on their target approach to helping the mice (Table 1). Systemic, which is the largest 
and most varied category was further divided into subcategories for analysis. 




Repair aberrant apoptotic pathways or inhibit pro-
apoptotic pathways




Repair deficit in both anterograde and retrograde axonal 
transport noscapine or anti-NRP1
Chemistry
Repair mishandling of metal or an imbalance in vital 
nutrients
DP-109, DP-460, Iron chelator VK-
28, magnesium pidolate
Energetics
Primarily target mitochondrial dysfunction and use of 
bioenergy (ATP, glucose) uridine, metformin, methimazole
Excitability
Repair or prevent excitotoxic damage through various 
mechanisms
riluzole, caffeine, progesterone, 
cannabinoid
Inflammation Modulate the inflammation process
inhibition of transglutaminase 2, 
rofecoxib
Oxidative 
Stress Lower the free radicals and oxidative stress levels riboflavin and pramipexole
Proteomics Repair or prevent protein aggregation. guanabenz and resveratrol
Systemic
Considered to have an effect at a systemic level, rather 
than cellular or subcellular level. Subdivided into: cell 
therapy, diet, exercise, growth factor, gene therapy, 
transplant, and unconventional
Stem cell therapy, light therapy, 
fibroblast growth factors
 3 
Polytherapy treatments were defined as treatments that belong to two or more of the 
nine general categories. Most of these were combinatorial treatment regimens that were 
applied simultaneously (creatine and rofecoxib or celecoxib (45)), but if a single treatment 
was considered to have effects on multiple categories (e.g. bee venom on apoptosis and 
inflammation (4)), then it was also classified as polytherapy. On the other hand, if two 
treatments of the same category were applied (e.g. PRE-084 and resveratrol in proteomics 
(59)), then it was classified as monotherapy. 
1.7 Disease Metrics 
Quantifiable data points were categorized into 3 groups of assessment modalities to 
investigate the effect on certain outcomes compared to others. Onset indicators included 
measures such as probability of onset, paralysis onset, onset age, etc. Survival signs 
included survival rate, age, cumulative survival, etc. Health status included the rest, 
comprising of a variety of metrics ranging from body weight to rotarod performance to 
grooming frequency. 
1.8 Normalization 
Each treatment data point was paired with a time-matched control from within the 
same article to create paired data points. Treatment effects were assessed by dividing the 
quantified outcome of a disease metric from the treated group by that of the control group 
to determine the fold of change in the mice condition caused by the treatment within the 
pair. Treatment effects resulting in values less than 1, those that performed worse than the 
control group, were excluded from the main analysis and only included in the harmful 
treatment sub-analysis. 
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1.9 Time Bin Selection 
The binning process provides a detailed assessment of different treatment 
categories’ effectiveness for each stage throughout the entire lifespan of the mice. Thus, 
the number of bins was selected as enough to capture significant trends while still retaining 
long term features of the dataset, such as the slight drops in average treatment effectiveness 
at pre-onset and mortal stages of disease. Each bin was required to hold approximately the 
same number of total data points to maintain comparability. 
All treatment-control paired data points were divided into 7 bins according to the 
mice age in days (Table 2). These bins correspond to and are grouped according to the 
disease stages of the mice model at that time: 3 before onset, onset, and 3 after onset, given 
that the average onset time for the untreated G93A SOD1 transgenic mouse model is 
99.27±1.79 days for mixed sex high copies B6SJL groups (6). 
1.10 Statistical Analysis 
Statistical significance of treatment ontologies was assessed with an ANOVA with 
post-hoc Tukey test for each time bin; a p-value of 0.05 considered the threshold for 
significance. To mitigate the bias from any one paper, each included study was weighted 
equally regardless of individual sample sizes of mice studied. All statistical tests were 
conducted in MATLAB R2014a software. Figures were generated in IGOR Pro. 
1.11 Results Layout 
In order to demonstrate trends found for specific temporal, ontological, and 
assessment modality relationships, the main ANOVA results will be presented in three 
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different ways: first by disease stage, second by ontology, and third by disease metric. 
References will be made in one section to the others to reiterate the data is the same no 
matter the organization strategy.
 6 
RESULTS  
1.12 Summary of Data Sources Used 
After filtering the database for established inclusion & exclusion criteria, 199 
papers were included in this meta-analysis, for a total of 5026 normalized data points 
(Table 2). These data points were further broken down into one or more of nine treatment 
categories, and into one of seven age groups correlating to the disease progression within 
the mice model chosen. The distribution of data per ontology found for this analysis 
corresponds with previous systematic review findings (5): systemic and inflammation 
papers are most common, while axonal transport is the least published in the field.  
Table 2 – Sources Overview: 5026 individual points were included in this analysis. 
 
When comparing the time of onset and death between treated and control mice in 
the 9 ontologies, excitability treatments were most effective at delaying onset, around 
Number of 




434 39 188 1183 682 713 791 321 1120 5026
0-70 77 4 42 218 115 77 182 31 185 867
71-85 39 7 26 161 108 85 101 29 83 418
86-100 79 7 40 228 163 130 121 66 204 963
101-110 60 1 23 129 87 114 78 45 165 640
111-120 81 11 281 202 120 124 113 65 187 853
121-130 48 2 13 113 39 108 111 43 146 563
131+ 50 7 14 129 50 75 89 42 150 552
Onset 37 0 37 73 24 40 83 17 59 356
Health 
Status 253 19 99 831 543 446 443 133 627 3024
Survival 144 21 68 279 174 227 265 171 434 1645
Inflammation Oxidative 
Stress




9.09 days. While oxidative stress was mediocre at best for onset, this category was the 
most effective at prolonging average survival at 14.21 days. Chemistry treatments 
indicated the least survival improvement in comparison with others (Figure 1). 
 
Figure 1 – Average delayed onset and survival data for each ontology. ANOVA 
analysis with post-hoc Tukey test determined no significant differences between 
ontologies for either onset or survival delay. 
1.13 Most treatments were administered pre-onset 
Across all ontologies, reported treatment start dates were collected and analyzed 
(Table 3). While the largest normalized treatment effects occurred post-onset, most 
treatments were administered in early life (Figure 2). The mean start dates were between 
41.72 and 54.22 days of age, which is well before the 100-day onset-mark for this mouse 
model. A Kruskal-Wallis and multiple comparison test yielded no significant differences 
between the treatment start dates of any of the ontologies. Considering that these 
treatments began pre-onset, and most of the effects happened post-onset, there is 




Table 3 – Mean ontology start dates. Onset, survival and start date of treatment 
data summary table for each ontology. The mean start dates of all ontologies were 
around 49.5 days of age, while the standard errors were around 1.818 (n = 6-122). 
 
 
Figure 2 – Paper reported start dates demonstrate that very few (0-5.7%) treatments 





Transport Chemistry Energetics Excitability Inflammation
Oxidative 








105.4 108.4 106.1 118.1 107.2 111.8 105.9 104.7 104.8 108.7
Difference 








137.6 135.2 128.7 138.4 144 139.8 135.7 141.3 143.6 138.9
Difference 




44.1±8.8 52.2±11.5 50.9±7.5 45.0±6.5 53.24.5 54.2±3.8 48.4±4.7 41.7±5.1 48.6±4.1 49.5±1.8
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1.14 Treatment Category Efficacy Changes Throughout Disease Progression 
All 5026 data points were included in an ANOVA analysis with a Post-Hoc Tukey 
test evaluating every category’s normalized treatment efficacy in every age group 
throughout disease progression in all assessment modalities (Figure 3). 
 
Figure 3 – Treatment category efficacy changes throughout disease progression. 
Organized by A) disease progression and B) individual treatment category. 0-100 
days: No one treatment performs significantly better prior to onset. 101-110 days: 
excitability treatments have the best effect around disease onset. 111-120 days: axonal 
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transport performs the best immediately following onset. Chemistry is significantly 
worse than a few other categories. 121-130 days: no trends emerge during the later 
disease stage. 131+ days: Apoptotic treatments are significantly more effective than 
systemic at end-stage. p < 0.05. 
1.14.1 1-70 days 
 When taking into account all disease measures, no treatments were notably more 
effective during the youngest age range (Figure 3). Within the specific assessment 
modalities, no significant relationship occurred for improving survival (Figure 6) or health 
status (Figure 5) metrics; the only significant relationships were apoptosis outperforming 
a few other treatments in delaying onset symptoms (Figure 4). 
1.14.2 71-85 days 
While the trend of no significant benefit for all measures (Figure 3) and health 
status (Figure 5) continues, there are some benefits for the other two assessment modalities. 
Apoptosis is almost twice as effective as any other treatment in delaying onset (Figure 4) 
and systemic displays significant benefit to the mice in prolonging survival characteristics 
(Figure 6). 
1.14.3 86-100 days 
While apoptosis had the most benefit for all measures (Figure 3) and health status 
(Figure 5), no category of treatments performed significantly better than another in the 
stage immediately preceding onset for all disease measures (Figure 3) as well as any metric 
sub-analysis (Figure 4-6). 
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1.14.4 101-110 days 
Analyzing all disease modalities, excitability treatments demonstrated a noticeably 
greater effect than all others (Figure 3); this was mostly due to its effects on the health 
status modality at this stage (Figure 5). There was an observed benefit from this treatment 
for onset delay, but inflammation was slightly better in this stage (Figure 4). Systemic 
continued the trend of being slightly better than others in survival, but overall all treatments 
have relatively the same benefit to the mice (Figure 6). 
1.14.5 111-120 days 
Axonal transport treatments were exceedingly more effective than every other 
category on all modalities combined (Figure 3). This occurred solely from this category’s 
ability to extend the survival of the mice significantly more than any other (Figure 6). 
Chemistry was especially ineffective in this stage (Figure 3). 
1.14.6 121-130 days 
There was no observable trend in any of the nine categories. However, most 
treatment categories showed at least twice the benefit in this stage compared to control data 
(Figure 3). 
1.14.7 131 days and after 
Chemistry, which had been consistently one of the least beneficial, had the highest 
effect at the end. Interestingly, this category’s efficacy during this stage came solely from 
prolonging survival (Figure 6), as it was the worst at improving health status measures 
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(Figure 5). Apoptosis was closely behind on all measures (Figure 3), and much more 
effective at health status (Figure 5). 
1.15 Treatment Category Efficacy Varies by Ontology 
 Overall, the apoptosis treatment category efficacy steadily increases in normalized 
treatment effect to control as the disease progresses; culminating in being one of the best 
categories at end-stage (Figure 3) due to its benefit for the health status and survival 
modalities at that time. This ontology also demonstrated a significantly higher benefit than 
all other treatments for delaying onset (Figure 4).  
While axonal transport had the least amount of data and was subsequently excluded 
from some assessment modality analyses, this category displayed the highest treatment 
effect immediately post-onset of any other category at any other age group due to its 
profound benefit in improving survival signs (Figure 6).  
Chemistry was close behind apoptosis for a steadily increasing treatment effect as 
the disease progressed (Figure 3); this category’s most notable benefit was extending end-
stage survival better than all other treatments (Figure 6).  
Energetics peaked in treatment effect during later disease stages (Figure 3), but was 
only once the best treatment for any assessment modality at any time, during a post-onset 
stage in survival (Figure 6).  
Excitability performed slightly above average during the early stages, but was 
significantly better than all others during the typical time of disease onset (Figure 3). This 
benefit is almost solely from the comparative improvement for health status disease metrics 
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(Figure 5). 
Inflammation gave an average benefit to the mice during early-life, but had one of 
the worst overall effects at end-stage. This treatment did have the highest effect of all 
ontologies in delaying onset at the 101-110 and the 111-120 days groups (Figure 4), but 
was not effective at prolonging survival (Figure 6). 
Oxidative stress usually fell in the middle of the categories and was never found to 
perform the best of any time or modality beyond the onset modality at the 121-130 days 
range.  
Proteomics consistently ranked in the bottom of the categories for all measures, until 
its high effect at end-stage (Figure 3). Within the onset sub-analysis, it had almost the same 
effect as inflammation at the 101-110 days range, but showed a sharp decline in the next 
bin and then did not have enough data beyond the 111-120 days group to assess its effect 
on onset.  
Systemic treatments were slightly more effective than other treatments during early-
life and, though not usually the best, consistently performed as one of the best categories 
in each modality throughout disease progression. 
1.16 Treatment Category Efficacy Varies by Disease Metric 
1.16.1 Onset 
When analyzing the normalized treatment effect of each category, a sub-analysis of 
just the measurements relating to onset provide more specific insight into how each 
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treatment is affecting the mice (Figure 4). Apoptosis had the most beneficial effect in early 
life, despite not indicating any significance in the main analysis (Figure 3). This treatment 
continues to stand out in the next stage of disease progression, and is found to have almost 
twice the benefit at the 71-85 age group than any other treatment. Its effect diminished just 
prior to onset: inflammation, excitability, and proteomics were the top three categories, but 
there were no significant differences in the 86-100 age range. Inflammation performed the 
best in the 101-110 days age group for delaying onset, and retained this status in the 111-
120 days group; proteomics was a close second in the former and apoptosis in the latter. 
While neither was significant, oxidative stress performed the best right before end-stage, 
and systemic at the end-stage 131+ days age group. Axonal transport did not have enough 
data to be included in this assessment modality, and several categories were excluded due 
to lack of data in the post-onset stages. 
Figure 4 – Analysis of onset assessment measures by category. Most notably, 
apoptosis is significantly more effective than all other categories at delaying onset 
symptoms during early life. p < 0.05.  
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1.16.2 Health Status 
All measurements not related to onset or survival were placed in the health status 
assessment modality and analyzed separately. While apoptosis consistently showed a high 
treatment effect during every pre-onset stage, correlating with the onset modality results, 
no significant trends emerged until the high benefit of excitability at the 101-110 day stage. 
This remarkable effect is very different to the treatment’s performance in the onset and 
survival analysis. While excitability’s benefit remained high until end-stage, inflammation 
was best at 121-130 days, and then axonal transport and apoptosis at the 131+ day stage. 
Every category contained enough data to be analyzed at each stage (Figure 5). 
Figure 5 – Analysis of only health status measures by category. Most notably, 
excitability was most beneficial at disease onset, while axonal transport and apoptosis 
were best at end-stage. p < 0.05. 
1.16.3 Survival 
Those measurements pertaining to the survival assessment showed no correlation to the 
onset or health status modalities. The treatment effects of all groups were similar from 
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early-stage until post-onset; systemic always performed the best in these age groups, and 
even demonstrated a significantly better effect than all others in the 71-85 days age group. 
Axonal transport had a treatment effect of almost 8, the highest of any in the entire analysis, 
at the 111-120 days age group. In the later disease stages, no significant trends emerged 
beyond systemic being the worst at prolonging survival, but the effects of each treatment 
were much higher than at early life (Figure 6). 
Figure 6 – Analysis of survival assessment measures by category. While all were 
relatively ineffective in early stages, systemic was consistently the best. Post-onset, 
axonal transport had a substantially larger effect on mice aged 111-120 days. p < 0.05.  
 
1.17 Systemic treatment subcategories also demonstrate trends throughout 
disease progression 
The systemic treatment category warranted a sub-analysis, not just because it was the 
group that contained the largest number of data points, but also due to this ontology 
encompassing a wider range of treatment modalities and containing treatments that are 
most studied to date (Figure 7). 
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Figure 7 – Systemic treatment subcategories have widely varied treatment 
effects at each disease stage. Most notably, growth factors consistently 
performed better than other subcategory at early life and again at onset until 
just before end-stage. The unconventional category was significantly better in 
early stages of life. p < 0.05. 
1.17.1 1-70 days 
Growth factors had the highest treatment effect of all systemic subcategories, 
performing significantly better than diet. The others category was a close second. 
1.17.2 71-85 days 
Treatment effects of most categories were comparable to those of the previous age 
group, yet growth factors’ effect fell to the average. The others subcategory indicated 
significantly better effects than the rest. 
1.17.3 86-100 days 
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All treatment effects remained relatively low, but growth factors became the most 
effective category again. 
1.17.4 101-110 days 
Growth factors’ benefit to the mouse remained the same, while all other categories 
performed better. The cell therapy category had the highest treatment effect within this age 
group. 
1.17.5 111-120 days 
Growth factors once again yielded the highest treatment effect, with cell therapy 
also showing relatively high benefit to the mice compared to control. 
1.17.6 121-130 days 
Growth factors reached its highest treatment effect in this age group. Exercise and 
unconventional were the worst at this stage. 
1.17.7 131 days and after 
While not demonstrating any statistically significant relationships, the diet 
subcategory had the highest treatment effect at end stage after being consistently towards 
the bottom before this. Exercise, another subcategory that had not previously performed 
well, was almost as beneficial to the mice. 
1.18 Some treatments could potentially harm mice 
 Disease measures with a normalized value of <1 were excluded from the main 
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analysis of treatment effectiveness and were compared separately. A total of 1350 negative 
treatment points were detected (as opposed to 5026 positive included in the main analysis). 
A few significant relationships were found, most notably between proteomics and several 
other treatments in the 86-100 days age groups; the only other relationships found were 
between systemic and a few other treatments at 111-120 days. Most of these harmful 
treatment values were isolated instances of one data point where control outperformed 
treatment, but the treatment effect would rise to >1 at the next measured time point and 
again be classified as beneficial. However, 48 out of 199 papers had negative treatments in 
4 or more time bins; 2 papers published consistent harm in all timebins (10, 11). Patel et 
al., a systemically treated group, specifically the diet subcategory, reported negative 
treatment effects in all 7 time bins, and 89 out 136 data points (65.4%) from this paper had 
<1 normalized value (10) (Figure 8). 
Figure 8 – Harmful treatments distribution by ontologies. While some 
treatment categories reported negative results more frequently than others, there was 




1.19 Post-onset measure better than pre-onset measures 
The normalized treatment effects of every category increased steadily throughout 
disease progression, with 121-130 or 131+ days being the most effective age groups. While 
this outcome is encouraging, considering that diagnosis and treatment would most likely 
not begin in an ALS patient pre-onset, these results are not unexpected given that as the 
disease progresses and the mices’ health deteriorates, a treatment has more room for a 
drastic improvement in the assessment modalities included in this analysis (Figure 9).  
Figure 9 – Defining the onset threshold at 100 days, the average effect of all 
treatments compared to control yielded significantly more impact after onset than 
prior to in all assessment modalities. (***p < 0.0001). 
 
1.20 Combination treatments better than monotherapy 
During pre-onset, the polytherapy treatments were not as effective as monotherapy 
(Figure 10). Post-onset, the combination treatments were becoming more effective than 
monotherapy treatments during the diseased states (111-120 and 121-130 days groups), 




Figure 10 – Comparison of the treatment effects of monotherapy and 
polytherapy treatments. Polytherapy treatment effect started to climb around disease 
onset and performed significantly better than monotherapy at the end stage 131+ days 
age group. * p < 0.05. 
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DISCUSSION 
1.21  “Best” treatment categories change with disease progression 
Results from this meta-analysis of different treatment categories in high copy G93A 
SOD1 transgenic mouse models throughout the entirety of their lifespan revealed that 
specific treatment approaches performed better than others during different stages of 
disease progression. 
1.21.1 Before Onset (0-100 days) 
Overall no category of treatments performs better than the others in stages 
immediately pre-onset. It has been noted in literature that ALS patients have less antecedent 
disease than the average population, possibly due to the overcompensation for the 
aberrancy (16). Also, it has been noted that certain disease parameters, such as the oxidative 
stress level in transgenic mice do seem to improve briefly preceding the onset (17). Such 
findings align with the results that the untreated group may be performing almost as well 
as the control group for most of the treatments, since the mice must be physiologically 
overcompensating for the impending disease. Another interpretation of this result could be 
that all treatments produce similar positive feedback from mice that none of them is better 
than the other in comparison. 
1.21.2 Onset (101-110 days) 
Excitotoxicity treatments perform better at the onset. Glutamate-induced 
excitotoxicity resulting in motor neuron death is one of the pathogenic mechanisms in ALS. 
As mSOD1 increases the sensitivity of the AMPA receptor to glutamatergic stimulation 
 23 
and disrupts mitochondrial function, affecting the surrounding astrocytes. Excitotoxicity 
treatments interrupt glutamatergic transmission and lower glutamate concentration, 
resulting in protection against motor neuron degeneration (18). There are excitability 
treatments known in literature to extend survival but not delay the onset, which is consistent 
with the findings of excitotoxicity cell death being a late phenomenon in mutant SOD1-
mediated neurodegeneration (19-23). The results from this study, however, indicate the 
opposite: treatments in excitability category are effective for onset during this stage while 
the survival metrics were not noticeably different from those of the other treatments. 
However, most of anti-excitotoxicity treatment effects came from non-survival/onset 
measures, which is consistent with previous findings, among them the fact that ceftriaxone 
significantly delayed the decrease in the body weight and muscle strength (19). 
1.21.3 After Onset (111 days of age and after) 
1.21.3.1 Early Diseased Stage  (111-120 days) 
Treatments targeting axonal transport category are effective during the early 
diseased stage. Axonal transport is known to start being compromised very early in mice 
lifespan, around 20-50 days (24, 25). A study even found that axons can degenerate without 
preceding transport deficits and vice versa (25). While treatments in axonal transport 
category are known to prolong survival (26, 27), the mechanisms are unclear as to how 
they may extend the survival, especially during 111-120 days of age. Perhaps more data 
and studies in the treatment group, which originally had the smallest sample size of all 
categories, will give a clearer picture of the effects on disease progression. 
1.21.3.2 Late Diseased Stage  (121-130 days) 
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All treatment groups performed better during the late diseased stage. In this 
intermediate state between the symptomatic state and late stage, high copies G93A mice 
are having more severe symptoms and rapidly deteriorated health (28). Thus, the effect 
from treatment regimens would show a better performance than earlier stages when the 
data is normalized. However, at a closer look, inflammatory performed 16% better than the 
average treatment effect. Besides playing a major role in the pathogenesis of motor neuron 
death in ALS, neuroinflammation accelerates disease progression (18). Thus recently, 
interest in inflammatory treatments has been growing (19). It has been suggested that early 
anti-inflammatory treatment is necessary to interrupt ALS-induced neuroinflammation 
(29), and the promising outcomes of the immunoregulatory treatments from the early stage 
of the mice’s lifespan are consistent with this postulation as inflammation category has a 
large number of pre-onset treatment. 
1.21.3.3 Late Stage  (131 days and after) 
Anti-apoptotic and chemistry treatments performed significantly better during late 
stage (131 days and after). Any data from the time at which the untreated G93A mice 
would normally die were classified in the last bin in the analysis. Most treatments do show 
an effect at this point due to the increased longevity of the treated mice, but only the anti-
apoptotic treatments perform significantly better than the other categories. This result is 
consistent with another review pointing out that agents that block apoptosis in ALS mice 
primarily affect disease endpoint (19). The anti-apoptotic treatments that were evaluated 
in this stage include zVAD-fmk, an enzymatic caspase inhibitor (8), AEOL 10150, a 
manganese porphyrin with anti-apoptotic properties (9), p75 knockout (30), melatonin (2), 
as well as other factors (Supplemental Table 1). However, some of this might be explained 
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by a greater number of studies classified as apoptotic being targeted at exploring the 
underlying mechanisms of ALS progression rather than testing prospective treatments, and 
may have limited predictive value. On the other hand, chemistry category had almost as 
great an effect as anti-apoptosis treatments, although not to a statistically significant extend 
due to its small sample size. Intracellular copper homeostasis was known not to be altered 
in the pre-symptomatic transgenic mice (31), and this may explain why treatments in 
chemistry category become effective only in the later stages of diseased mice life. 
1.22 Within Systemic Category 
Unconventional subcategory performed significantly well in early life (0 - 85 days). 
Interestingly, the category that includes unconventional treatments such as light therapy or 
castration outperformed the other well-defined and established and advanced approaches 
like gene therapy. A possible explanation could be that these treatments have more 
immediate effect than other subcategories like growth factors injection or gene therapy. 
Growth factor subcategory performed better than others in immediate pre-onset 
stage (86 - 100 days) and symptomatic stage (111-130). With the direct effects on neuronal 
growth, axonal outgrowth and neuroprotection, growth factor subcategory treatments can 
specifically inhibit superoxide-induced cell death and promote neuronal survival by 
interacting with proteins having neurotrophic or neurotoxic properties (32, 33). With its 
prominent potential, growth factors have been the subject of multiple clinical trials for ALS 
treatment since the 1990s, but the results from these trials have been either slowed disease 
progression (34) or safe but no improvement or no difference (35, 36). Our results also 
found that this subcategory improves all measures throughout the symptomatic stage but 
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not during the last stage.  
Cell transplantation has better effect during the onset stage (101 - 110 days). The 
cell transplantation approach has been gaining a lot of attention lately as a powerful tool 
for treating neurological disorders such as ALS. These therapies aimed at cell replacement 
or neuroprotection while stimulating patient’s own repair mechanisms so that the 
transplanted stem cells become integrated into the system and infiltrate the areas affected 
by disease (37). In the ALS case, using stem cell could prevent motor neurons from dying 
as they migrate into the spinal cord and induce motor recovery (38). A clinical trial has 
found mesenchymal stem cells transplantation in ALS to be safe and well-tolerated in 26 
patients and at 6 month after treatment, 80% of the patients improved by more than 35% 
and 67% by more than 50% (39). 
During the late stage (141 days onward), diet and exercise became more effective. 
While diet and exercise are known to improve physiological parameters in completely 
normal mice (and human beings), and it may be the reason why the mice that had not 
developed symptoms still showed treatment effects. However, in some studies, the 
manipulations of exercise and dietary restrictions resulted in conflicting and fluctuating 
results.  Dietary restriction was reported to improve motor performance but significantly 
worsen the ultimate outcome in mice by hastening disease onset (11). Low and moderate 
treadmill exercise was beneficial in transgenic mice although with opposing gender effects 




1.23 Combination therapy is the future of ALS treatment 
Comprising 7% (567 / 7607) of the data in this analysis, combination therapy 
were treatments categorized into more than one ontology. This subgroup is significantly 
more beneficial to the mice during the later disease stage of 123-140 days (Figure 6). 
This is consistent with previous literature demonstrating that combination treatments 
have improved disease metrics more effectively than either of the treatments conducted 
alone. A synergistic approach to such a complex disease would be more likely to 
address all the varied factors involved in the ALS instability.  
1.24 Treatments administered pre-onset show most benefit post-onset 
Most treatments in this meta-analysis were most effective at later disease stages 
than earlier. This late benefit could be due to the fact that in transgenic mice, ALS 
symptoms and body condition degradation are exacerbated in later stages, so there is 
naturally a higher chance for dramatic improvements. Interestingly, most of the studies also 
began administering treatments prior to onset, so the benefit to the mice was a delayed 
outcome. This result correlates with many recent studies indicating pretreating at-risk 
patients had the best results for various neurological diseases. Because of these promising 
results, future experiments are being designed to test the effect of pretreating patients prior 
to disease onset. One ongoing study aims to test the efficacy of drug administration before 
disease onset on a family in Antioquia, Colombia whose rare gene mutation guarantees 
their development of early Alzheimer’s disease (51). Only a few Alzheimer’s patients 
benefitted from the drug so far, but it is believed the initial time of treatment was potentially 
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too late. Nevertheless, pretreating patients prior to onset has been studied in various 
diseases (52-54) and future research will expand upon this proactive approach idea. 
1.25 Modality assessment can distort apparent treatment efficacy 
 As demonstrated by the assessment modality analyses, certain ontologies are 
particularly effective in delaying onset, prolonging survival, or improving quality of life 
health status measures, but not all three. For example, inflammation and apoptosis were 
most effective at delaying onset at differing disease stages. During early life, 
neuroinflammation may be the most aggravating instability that accelerates ALS 
progression (18), but seems to be less important later on as other issues arise. While 
research has shown that blocking apoptosis towards end-stage should be a primary target 
(19), this seems to do nothing to prolong survival, but will reduce onset characteristics and 
improve the health measures in the mice (Figure 4). Conversely, treatments targeting 
axonal transport were most effective in delaying survival only; there could potentially be 
more benefit to this targeted approach, but it is the least researched in the field, and the 
lack of data excluded this ontology from some of the analysis. Axonal transport slowing 
occurs very early in the disease progression (55), with the anterograde mitochondrial 
transport most affected by the SOD1 mutation. Detecting and immediately treating these 
issues during early-onset should be a priority (56), and could continue to be beneficial later 
in life (Figure 4B). 
 Treatments may be more beneficial in improving only survival or onset, but given 
the disparity in treatment efficacy for these specific assessments compared to the health 
measures modality, how the clinical progression of ALS is tracked will affect results. The 
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health measures analysis included the standard tracking parameters: rotarod performance, 
grip strength, body weight, etc., as well as any other assessment used, but the effectiveness 
of these in monitoring the mice has been debated (57). Further research into which 
assessments are more reliable in determining onset and tracking disease progression may 
help standardize treatment evaluations. 
1.26 Not all intuitive treatments are helpful. 
Epidemiological studies indicate that multiple environmental agents are responsible 
for triggering ALS (58). Due to the complexity of ALS, some treatments were intended to 
improve, yet they resulted negatively in disease measures (Figure 8). For example, one 
included study tested the effect of caloric restriction, which hypothetically increases 
mitochondrial oxidative capacity. However, increasing mitochondrial oxidative capacity 
could be only observed in female G93A mice not male G93A mice (10). 65.4% of results 
after caloric restriction treatment had <1 normalized values, and they could have been 
found in all 7 time bins, which indicates that caloric restriction treatment was a harmful 
treatment. According to the result of this study, not all intuitive treatments benefit ALS, so 
treatments should be chosen carefully and examined in the context of the entire physiology 






This meta-analysis was conducted in order to aggregate existing published data on the 
comparative benefits of various treatment options in the SOD1 G93A transgenic mouse. 
By determining the most promising pathophysiological approaches, future research can be 
more focused on the best treatments and advance the field at a further rate. The results have 
determined that there is a temporal relationship between treatment approach and disease 
progression, which supports the theory of combinatorial medicine to match the complexity 
of a neurodegenerative disease. It also demonstrates that starting a treatment before disease 
onset will yield benefits throughout the rest of disease progression all the way to end-stage, 
which could have an impact on those patients that develop familial ALS. Hopefully future 
research will yield an accurate predictive model to anticipate the dominant instability 
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